Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company dedicated to transforming cancer care, announced that its leadership team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 p.m. Eastern Time. The session will provide investors and industry professionals with insights into the company’s strategic direction, technology advancements, and long-term vision. A live audio webcast of the presentation will be accessible via Veracyte’s investor relations website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 90 days following the live event. Veracyte is committed to improving cancer diagnosis and treatment by delivering high-impact diagnostic solutions. The company’s Veracyte Diagnostics Platform leverages comprehensive genomic and clinical data, advanced bioinformatics, artificial intelligence, and a robust evidence-generation engine. These capabilities enable the development of clinically validated tests that support better decision-making at critical points in patient care. The platform also drives long-term reimbursement and inclusion in clinical guidelines, while fueling ongoing innovation and expansion of the company’s diagnostic pipeline. For more information about Veracyte and its mission to advance cancer diagnostics worldwide, visit www.veracyte.com or follow the company on LinkedIn and X (formerly Twitter).